Leading the Way in Life Science Technologies

GEN Exclusives

More »

Market and Technology Analysis

More »
Dec 27, 2013

China’s In Vitro Diagnostics Marketplace, Part I

Although China has a vibrant domestic CLIA sector, the country’s MDx market is expanding rapidly and opportunities abound.

China’s In Vitro Diagnostics Marketplace, Part I

There are around 20,000 clinical labs in China, which roughly corresponds to the number of hospitals in the country. [Photo Credit: © Elena Kovaleva/Fotolia.com]

  • This GEN Report Provides a Snapshot of the China In vitro Diagnostics Marketplace based on Primary Market Analysis

    • Infectious Disease Testing Contributes to the Bulk of this Space Currently—with Few Disease Classes Dominating Revenue Generation Today
    • The Field is Fragmented with Thousands of End-User Laboratories where Testing is Performed
    • Both Local as well as Multinational Companies are Active in this Marketplace
    • Oncology Testing Represents a Future Growth Opportunity for this Marketplace and Offers Entry Opportunity to Technology Providers to Establish Partnerships with Local Companies to Participate in this Growth

     Click here to download this PDF report



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »